SAN DIEGO & TOKYO--(BUSINESS WIRE)--
Cytori Therapeutics, Inc. (NASDAQ: CYTX) announced today that its
licensee Kerastem Technologies, LLC, has expanded STYLE, its US phase II
clinical trial investigating early stage female and male pattern hair
loss. In this expansion, Kerastem has added new trial sites in New York
and New Jersey to complement the currently enrolling sites in Los
Angeles and Miami.
“Kerastem is dedicated to bringing Cytori technology to market for men
and women with alopecia,” said Dr. Marc H. Hedrick, President & CEO of
Cytori. “The Kerastem team has assembled an excellent clinical team. If
this trial is successful, we believe the Kerastem/Cytori partnership
could provide effective treatment for people dealing with hair loss and
create a significant new revenue source for Cytori, creating value for
our stockholders.”
STYLE is a phase II randomized, blinded, and controlled investigation of
Kerastem therapy in early stage female and male pattern baldness. STYLE
is approved to enroll up to 70 patients at up to eight (8) centers
within the United States.
Outside of the United States, Kerastem is actively involved in market
development, with Kerastem therapy currently being offered at a number
of clinics in Europe & Japan.
To learn more about Kerastem or the STYLE Clinical Trial, please visit www.kerastem.com
or https://clinicaltrials.gov/ct2/show/NCT02503852?term=Kerastem&rank=1
About Cytori
Cytori Therapeutics is a late stage cell therapy company developing
autologous cell therapies from adipose tissue to treat a variety of
medical conditions. Data from preclinical studies and clinical trials
suggest that Cytori Cell Therapy™ acts principally by improving blood
flow, modulating the immune system, and facilitating wound repair. As a
result, Cytori Cell Therapy™ may provide benefits across multiple
disease states and can be made available to the physician and patient at
the point-of-care through Cytori’s proprietary technologies and
products. For more information visit www.cytori.com.
About Kerastem
Kerastem Technologies, LLC is a private company owned by Bimini
Technologies, and holds global rights to commercialize Cytori Cell
Therapy for alopecia and hair related indications. The Bimini portfolio
of products also includes Puregraft, the world’s leading fat grafting
solution.
Cautionary Statement Regarding Forward-Looking Statements
This press release includes forward-looking statements regarding events,
trends and business prospects, which may affect our future operating
results and financial position. Such statements, including, without
limitation, potential benefits to Cytori and its stockholders of
successful clinical trials and the positive effects of such trials on
Cytori’s partnerships, are all subject to risks and uncertainties that
could cause our actual results and financial position to differ
materially. Some of these risks and uncertainties include, but are not
limited to, inherent risk and uncertainty in the protection intellectual
property rights, regulatory uncertainties, risks in the conduct of
clinical trials, risks in the collection and results of clinical data,
final clinical outcomes, dependence on third party performance,
performance and acceptance of our products in the marketplace, as well
as other risks and uncertainties described under the heading "Risk
Factors" in Cytori's Securities and Exchange Commission Filings on Form
10-K and Form 10-Q. We assume no responsibility to update or revise any
forward-looking statements to reflect events, trends or circumstances
after the date they are made.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160121005249/en/
Source: Cytori Therapeutics, Inc.